Breaking News Instant updates and real-time market news.

ALIOF

Actelion

$184.01

30.46 (19.84%)

, JNJ

Johnson & Johnson

$113.53

-0.6 (-0.53%)

13:22
11/28/16
11/28
13:22
11/28/16
13:22

Potential Actelion deal worthwhile for J&J, WSJ says

A potential takeover of Actelion (ALIOF) by Johnson & Johnson (JNJ) would be expensive but worth it for the U.S. company, Charley Grant contends in the Wall Street Journal's Heard on the Street column. Such a deal would entail major risk, as deals of this magnitude usually do, and J&J may need to pay a further takeover premium to close an acquisition, the column notes. There is also risk associated with generic competition that Actelion's Tracleer drug may face, the column says. Despite those warning signs, scaling up its pharmaceutical operations is a good strategy for J&J, Grant says. Sales in the company's pharmaceuticals unit grew 11.8% from a year ago in Q3, and Actelion's drugs portfolio could add some diversification to J&J's lineup, the column says. Reference Link

ALIOF

Actelion

$184.01

30.46 (19.84%)

JNJ

Johnson & Johnson

$113.53

-0.6 (-0.53%)

  • 29

    Nov

ALIOF Actelion
$184.01

30.46 (19.84%)

11/28/16
WELS
11/28/16
NO CHANGE
WELS
Actelion could be acquired for $215 per share, says Wells Fargo
After Johnson & Johnson (JNJ) said that it's in preliminary talks about a deal with Actelion (ALIOF), Wells Fargo estimates that J&J could buy Actelion for $215 per share. The firm thinks that other bidders could emerge for Actelion. It estimates that the deal could be accretive to J&J's EPS by about 5%. Wells keeps an Outperform rating on J&J.
JNJ Johnson & Johnson
$113.53

-0.6 (-0.53%)

10/19/16
LEER
10/19/16
NO CHANGE
Target $140
LEER
Outperform
Johnson & Johnson should be bought on weakness, says Leerink
Leerink analyst Danielle Antalffy believes the recent selloff in Johnson & Johnson's shares was overdone and would recommend buying on weakness. The analyst views the company as well-equipped to manage the inevitable Remicade headwind and continues to believe Johnson & Johnson can drive improving top-line growth in 2017. She reiterates an Outperform rating and $140 price target on the shares.
10/19/16
UBSW
10/19/16
NO CHANGE
Target $144
UBSW
Buy
Johnson & Johnson has potential upside from expanding pipeline, says UBS
UBS analyst Matt Miksic noted Johnson & Johnson delivered a solid quarter and said he believes there is upside to his Buy thesis. The analyst cited the company's expanding pipeline, capital allocation strategy, and contracting across its broad portfolio and patient assistance programs is expected to help mitigate pressure from biosimilar competition. Miksic reiterated his Buy rating and raised his price target to $144 from $137 on Johnson & Johnson shares.
11/09/16
RBCM
11/09/16
NO CHANGE
RBCM
Johnson & Johnson should be bought on recent weakness, says RBC Capital
After meeting with J&J's VP, Investor Relations, RBC Capital analyst Glenn Novarro says that the company's Q3 pharma results indicate that the growth of its major drugs can more than offset any declines in Remicade sales next year. The analyst quotes J&J as saying that it has not been using price hikes to increase its sales, and he thinks that the company's diverse business model will allow it to avoid being hurt by any regulatory pressures. He is upbeat on the company's efforts to increase its margins and notes that its medical device results have improved. Novarro keeps a $133 price target and an Outperform rating on the shares.

TODAY'S FREE FLY STORIES

EEM

MSCI Emerging Markets Index

$45.63

-0.01 (-0.02%)

10:10
09/21/17
09/21
10:10
09/21/17
10:10
Options
Friday the 13th put buyer in iShares Emerging Markets Fund »

Friday the 13th put buyer…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMBA

Ambarella

$46.15

-0.29 (-0.62%)

, GOOG

Alphabet

$931.58

9.77 (1.06%)

10:06
09/21/17
09/21
10:06
09/21/17
10:06
Recommendations
Ambarella, Alphabet, Alphabet Class A analyst commentary  »

Smart doorbell business…

AMBA

Ambarella

$46.15

-0.29 (-0.62%)

GOOG

Alphabet

$931.58

9.77 (1.06%)

GOOGL

Alphabet Class A

$947.54

10.68 (1.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Oct

  • 22

    Oct

  • 29

    Nov

CCC

Calgon Carbon

$21.33

8.125 (61.55%)

10:06
09/21/17
09/21
10:06
09/21/17
10:06
Downgrade
Calgon Carbon rating change  »

Calgon Carbon downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ASMB

Assembly Biosciences

$30.49

-0.43 (-1.39%)

10:05
09/21/17
09/21
10:05
09/21/17
10:05
Conference/Events
Assembly Biosciences management to meet with Jefferies »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 26

    Sep

  • 27

    Sep

  • 28

    Sep

AR

Antero Resources

$20.34

0.04 (0.20%)

10:03
09/21/17
09/21
10:03
09/21/17
10:03
Downgrade
Antero Resources rating change  »

Follow-up: Antero…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OMP

Oasis Midstream Partners

, OAS

Oasis Petroleum

$8.68

-0.23 (-2.58%)

10:03
09/21/17
09/21
10:03
09/21/17
10:03
Syndicate
Breaking Syndicate news story on Oasis Midstream Partners, Oasis Petroleum »

Oasis Midstream Partners…

OMP

Oasis Midstream Partners

OAS

Oasis Petroleum

$8.68

-0.23 (-2.58%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 27

    Sep

  • 21

    Sep

10:02
09/21/17
09/21
10:02
09/21/17
10:02
General news
Leading Indicators data reported »

August Leading Indicators…

GLD

SPDR Gold Trust

$122.83

-0.79 (-0.64%)

10:01
09/21/17
09/21
10:01
09/21/17
10:01
Options
One-day put seller in SPDR Gold Fund »

One-day put seller in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:00
09/21/17
09/21
10:00
09/21/17
10:00
General news
Fed funds futures are little changed inside a very narrow trading ranges »

Fed funds futures are…

ARI

Apollo Commercial

$18.35

0.065 (0.36%)

09:59
09/21/17
09/21
09:59
09/21/17
09:59
Conference/Events
Apollo Commercial management to meet with JMP Securities »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

ALB

Albemarle

$135.68

-0.405 (-0.30%)

09:59
09/21/17
09/21
09:59
09/21/17
09:59
Conference/Events
Albemarle management to meet with Seaport Global »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 27

    Sep

AFSI

AmTrust

$12.90

0.01 (0.08%)

09:57
09/21/17
09/21
09:57
09/21/17
09:57
Conference/Events
AmTrust management to meet with JMP Securities »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

AAPL

Apple

$156.07

-2.66 (-1.68%)

09:57
09/21/17
09/21
09:57
09/21/17
09:57
Technical Analysis
Technical View: Apple edges below uptrend support line »

The shares were last at…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

AR

Antero Resources

$20.21

-0.09 (-0.44%)

09:56
09/21/17
09/21
09:56
09/21/17
09:56
Downgrade
Antero Resources rating change  »

Antero Resources…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALKS

Alkermes

$50.66

0.12 (0.24%)

09:55
09/21/17
09/21
09:55
09/21/17
09:55
Hot Stocks
Alkermes CEO highlights study showing opioids reduce life expectancy »

Alkermes CEO Richard Pops…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

APC

Anadarko

$47.29

2.48 (5.53%)

, PEG

PSEG

$45.88

0.645 (1.43%)

09:55
09/21/17
09/21
09:55
09/21/17
09:55
Options
Early notable gainers among liquid option names on September 21st »

Notable gainers among…

APC

Anadarko

$47.29

2.48 (5.53%)

PEG

PSEG

$45.88

0.645 (1.43%)

SLG

SL Green Realty

$98.99

1.27 (1.30%)

TSS

TSYS

$68.28

0.83 (1.23%)

CF

CF Industries

$35.50

0.31 (0.88%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

  • 25

    Sep

  • 27

    Sep

  • 05

    Nov

AMD

AMD

$13.74

0.62 (4.73%)

09:53
09/21/17
09/21
09:53
09/21/17
09:53
Options
Flurry of activity in AMD calls early-Thursday »

Flurry of activity in AMD…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OMP

Oasis Midstream Partners

, OAS

Oasis Petroleum

$8.83

-0.085 (-0.95%)

09:51
09/21/17
09/21
09:51
09/21/17
09:51
Syndicate
Breaking Syndicate news story on Oasis Midstream Partners, Oasis Petroleum »

Oasis Midstream Partners…

OMP

Oasis Midstream Partners

OAS

Oasis Petroleum

$8.83

-0.085 (-0.95%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 27

    Sep

  • 21

    Sep

KEG

Key Energy

$12.59

-0.05 (-0.40%)

09:50
09/21/17
09/21
09:50
09/21/17
09:50
Initiation
Key Energy initiated  »

Key Energy initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

EXPE

Expedia

$143.01

1.54 (1.09%)

, GOOG

Alphabet

$931.58

9.77 (1.06%)

09:49
09/21/17
09/21
09:49
09/21/17
09:49
Periodicals
Expedia CEO says HomeAway unit profit goal may need shifting, Skift reports »

Expedia (EXPE) CEO Mark…

EXPE

Expedia

$143.01

1.54 (1.09%)

GOOG

Alphabet

$931.58

9.77 (1.06%)

GOOGL

Alphabet Class A

$947.54

10.68 (1.14%)

AMZN

Amazon.com

$973.21

3.35 (0.35%)

MSFT

Microsoft

$74.94

-0.5 (-0.66%)

AAPL

Apple

$156.07

-2.66 (-1.68%)

FB

Facebook

$172.17

-0.35 (-0.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

  • 02

    Oct

  • 22

    Oct

  • 29

    Nov

HON

Honeywell

$139.09

0.4 (0.29%)

09:48
09/21/17
09/21
09:48
09/21/17
09:48
Recommendations
Honeywell could rally over 14% on portfolio shakeup, says Deutsche Bank »

Honeywell is expected to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MBUU

Malibu Boats

$28.53

0.2 (0.71%)

09:48
09/21/17
09/21
09:48
09/21/17
09:48
Periodicals
Breaking Periodicals news story on Malibu Boats »

Malibu Boats mentioned…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GPRO

GoPro

$10.66

-0.31 (-2.83%)

09:47
09/21/17
09/21
09:47
09/21/17
09:47
Recommendations
GoPro analyst commentary  »

GoPro unit and earnings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

09:46
09/21/17
09/21
09:46
09/21/17
09:46
General news
Bloomberg Consumer Comfort Index Level data reported »

Week of 9/17 Bloomberg…

JD

JD.com

$44.44

0.11 (0.25%)

09:45
09/21/17
09/21
09:45
09/21/17
09:45
Recommendations
JD.com analyst commentary  »

JD.com estimates cut…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.